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Abstract The embryonal tumor with abundant neuropil
and true rosettes is a rare and highly malignant variant of
embryonal brain tumors. It usually affects infants and
young children under the age of 4 years and exhibits a very
aggressive course with a dismal prognosis. For the 68
cases reported to date the mean age at diagnosis was
25.42 months (range 3–57 months). Survival data are
available for 48 children (including our case): the median
overall survival is 13.0 months, though 6 (9 %) of the
children have had a relative long survival ([30 months).
The aggressive combined treatment, involving primary
surgical tumor removal, adjuvant polychemotherapy,
including high-dose chemotherapy with stem cell trans-
plantation, radiotherapy and radiochemotherapy, might
play an important role in the longer survival. We have
performed a literature review and we present here a mul-
timodal-treated case of a 2- year-old girl with a long sur-
vival, who was reoperated when recurrence occurred. The
residual tumor demonstrated a good response to temo-
zolomide radiochemotherapy (craniospinal axis ? boost)
and followed by maintenance temozolomide. The descri-
bed complex aggressive treatment option might be con-
sidered for future cases of this tumor entity.
Keywords ETANTR ! Radiochemotherapy !
Craniospinal axis ! Temozolomide
Introduction
The embryonal tumor with abundant neuropil and true
rosettes (ETANTR) was first described in 2000 by Eberhart
et al. [1], who reported on 7 and 2 additional children with
this central nervous system (CNS) tumor. Histologically,
the presence of undifferentiated neuroepithelial cells, broad
bands of well-differentiated neuropil islands, and ependy-
moblastic rosettes are characteristic for this tumor entity
[2]. C19MC gene amplification is also characteristic for
this tumor entity and predicts an unfavorable clinical
course [3, 4]. The 2007 WHO classification of CNS tumors
categorized embryonal neoplasms in three groups: medul-
loblastoma, atypical teratoid/rhabdoid tumor and CNS
primitive neuroectodermal tumor (PNET). The highly
aggressive ETANTR is briefly mentioned in connection
with the description of CNS PNETs, and should probably
be regarded as a separate entity [5–8]. Approximately 70
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cases of this rare and malignant pediatric embryonal brain
tumor have been reported to date [1, 2, 9–30]. Usually very
young children are affected and a slight female predomi-
nance is observed [1]. We report here on a 2-year-old girl
who presented with ETANTR of the left cerebellum and
the left occipital lobe, which later recurred. This is the first
report of long term survival of a patient with this kind of
tumor even after recurrence.
Case report
A previously healthy 2-year-old girl was admitted to the
local hospital with a history of a few weeks of headache,
nausea, vomiting, tic, unsteady gait, and disturbances in
coordination. Magnetic resonance images (MRI) of the
brain revealed a contrast-enhancing lesion 6 cm in diam-
eter in the left cerebellum and left occipital lobe. No signs
of spinal metastasis were detected. The girl was operated in
May 2010 and gross total resection (GTR) of the tumor was
performed. Histopathological examination of the tumor
sample revealed highly cell- and vessel-dens blue-celled
tumor tissue with necroses and hemorrhages. The hyper-
chromatic tumor cells with mainly round nuclei and high
nucleus/cytoplasm ratio formed clusters and were poorly
differentiated. The mitotic ratio was high: 25 mitoses per 1
high-power field. Numerous multilayer perivascular, and
ependymal true rosettes and broad bands of neoplastic
neuropil islands could be observed. Immunohistochemical
analysis indicated CD99, vimentin, synaptophysin, glial
fibrillary acidic protein, epithelial membrane antigen,
neurofilament, BAF47 and integrase interactor-1 positivity.
The proliferation marker (MIB-1) showed focally high
labelling index (up to 60 %), and ETANTR was diagnosed
(Fig. 1). Detailed molecular profiling of the tumor revealed
two genetic variations, involving the I391 M of the
PIK3CA which is a known polymorphism, and N1118D
and the APC gene, previously described as germline vari-
ants associated with an increased risk of familial adeno-
matosus polyposis [31] and frequently mutated (29.2 %) in
brain tumors [32]. The girl was then treated according to
the Medulloblastoma 2008 high-risk protocol (2 cycles of
vincristine 1.5 mg/m2, cyclophosphamide 2 9 1 mg/m2,
and etoposide 4 9 100 mg/m2; 2 cycles of vincristine
1.5 mg/m2, carboplatin 2 9 200 mg/m2, and etoposide
4 9 100 mg/m2; 2 cycles of vincristine 1.5 mg/m2, cis-
platin 2 9 40 mg/m2, and etoposide 4 9 100 mg/m2; and
weekly adjusted intrathecal triplet altogether 7 times). In
November 2010 she underwent autologous stem cell
transplantation (SCT) with busulfan, thiotepa and etopo-
side. The patient became symptom-free, and her cognitive
and physical development were normal. A control MRI
scan in December 2012 (31 months after the operation)
revealed a 50 9 45 9 30 mm cystic lesion with a
12 9 33 9 5 mm contrast-enhancing mass inside it in the
left occipital lobe, and a 30 9 17 9 18 mm intensive,
inhomogeneous, contrast-enhancing lesion in the occipital
part of the tentorium (Fig. 2). The spine was free of dis-
ease. The girl was reoperated and subtotal resection (STR)
was performed. Thereafter, she received craniospinal irra-
diation (CSI), with 32 Gy in 1.6 Gy daily fractions (fr)
followed by chemo-radiotherapy (CRT) comprising tumor
bed (tb) boost with 24 Gy in 1.6 Gy/fr and a residual tumor
boost with 6 Gy in 1.5 Gy/fr supplemented with 75 mg/m2
temozolomide daily. No anesthesia was necessary during
radiotherapy. She has subsequently continued on 150 mg/
m2 temozolomide without dose escalation to 200 mg/m2
due to haematological side effects until September 2014.
The control MRI in August 2014 (4 years after the initial
diagnosis and 21 months after the recurrence) revealed a
residual 24 9 16 9 24-mm cystic lesion without any solid,
contrast-enhancing mass (Fig. 3). The girl is currently
disease-free, has no neurological symptoms or cognitive
deficits and has been admitted to a bilingual primary
school.
Discussion
Our literature review indicated 69 reported cases [1, 2, 9–
30] including our case since the first description of
ETANTR by Eberhart et al. in 2000 [1]. The available
clinical data demonstrate, that these tumors affect exclu-
sively children, usually under the age of 4 years in different
localizations throughout the CNS [9]. The prognosis is
regarded as extremely poor, though there has been one case
with an event-free survival of up to 7 years after GTR and
CRT: CSI with 36 Gy and a boost to 55.8 Gy supple-
mented with carboplatin and vincristine, and chemotherapy
(ChT) over a period of 6 months with cisplatin, vincristine
and cyclophosphamide [10]. There have been only 7
reports, including our case, involving beneficial adjuvant
treatment after tumor recurrence (Table 1). In these 7 cases
the mean age at the time of the diagnosis was 24.9 months
(range 16–36 months), with a male: female ratio of 3:4. At
a median follow-up of 15 months 3 children died, and 4
were alive. Each of this 7 children underwent primary
operation: STR in 4/7 and GTR in 3/7 cases. Thereafter 4
children received combined ChT (vincristine, etoposide,
cyclophosphamide, carboplatin, ifosfamide, thiotepa and
methotrexate), 2 received intrathecal ChT (cytarabine and
methotrexate) and autologous SCT, and 1 of these 2 chil-
dren was treated by radiotherapy (RT) to the tb with 54 Gy.
Tumor recurrence was detected after a mean of
11.6 ± 8.60 months, 6 children were reoperated (4 STR
and 2 GTR) while 1 child received only combined ChT and
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RT. 5 of the reoperated 6 children received combined ChT,
2 of them SCT, 1 proton CSI and our case CSI with 32 Gy
and tb CRT with 30 Gy and 75 mg/m2 temozolomide
daily.
Alexiou et al. [9] published a literature review of the
available case reports and concluded, that patients who
underwent STR or GTR had a significant survival benefit in
comparison with patients on whom only biopsy could be
performed (14 vs. 6 months, p = 0.006) but there were no
major differences between the STR and GTR groups. In our
analysis of the 7 recurring cases tumor recurrence was
somewhat faster among the STR patients than among the
GTR group (10.3 ± 0.85 vs. 14.0 ± 8.08 months, p =
0.589) with no significant difference in overall survival (OS)
Fig. 1 Hematoxilin-eosin staining showing embryonal tumor with
the characteristic abundant neuropil and the prescence of multilayered
rosettes (a). The proliferation marker (MIB-1, KI67) reveals high
labelling index, focally up to 60 % (b). There is synaptophysin
immunoreactivity both in the neuropil and in the rosettes (c).
Immunostaining shows p53 positivity (d)
Fig. 2 T2 weighted MRI shows the tumor recurrancy in the left occipital lobe (a) and in the postoperative cystic lesion in the left cerebellum and
in the tentorium (b)
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neither (26.3 ± 3.25 vs. 24.7 ± 9.93 months, p = 0.153).
6/7 children were reoperated and interestingly we found that
in cases of STR (4/6) as second surgery the mean OS was
longer than was in cases of GTR (2/6): 40.5 ± 7.36 vs.
12.5 ± 0.50 months, but because of the small number of
patients we must not conclude that STR would be more
beneficial than GTR as second surgery.
The majority of the children 6/7 received adjuvant
combined high-dose ChT before and/or after the tumor
recurrence. In the 3/7 children [1, 10, 11] who did not
receive any adjuvant therapy, the tumor recurred faster
than in the children treated with ChT (9.00 ± 2.51 vs.
14.00 ± 5.35 months).
4/7 Children received sequential autologous SCT after
high-dose ChT [1, 10, 12] and had a better mean OS
(31.25 ± 8.89 vs. 15.67 ± 1.09 months).
Focal RT with 54 Gy as adjuvant treatment was
administered together with ChT and SCT in only 1 case
[12]. This girl was 33 months old at the time of the diag-
nosis (the second oldest among the 7 cases) and was
probably able to cooperate in RT with anesthesia. Three
children (including our case) received adjuvant RT after
tumor recurrence: 50.4 Gy to the tb [13]; CSI with protons
(the dose is not available) [14]; and our case with 32 Gy
CSI and a 30 Gy tb boost in 1.6 Gy fr-s with concomitant
75 mg/m2 temozolomide daily. The children who received
RT (4/7) had a longer mean OS than that of the non-irra-
diated children (31.5 ± 8.76 vs. 24.0 ± 4.90 months). The
review by Alexiou et al. [9] found that the children who
were irradiated had a significant survival benefit relative to
non-irradiated children (16 vs. 11 months, p = 0.029).
For the 7 cases treated at least surgically after tumor
recurrence we found a quite high mean OS (33.7 ±
6.68 months) which is rather unusual in this tumor entity.
Alexiou et al. [9] reported an OS of 13.1 months. Our lit-
erature search revealed 6 (including our case) unusually
Fig. 3 T2 weighted MRI shows the residual left occipital cystic
lesion after the second surgery and RCT
Table 1 Reported cases of recurrent ETANTR with additional treatment after recurrence
A/G Loc. Treatment Outcome/FU Ref.
24 m/F L front. STR ? 11 m RD ? STR; IFO, CBDCA, VP-16; SCT FoD, 30 m [1]
17 m/M R pariet. GTR ? 4 m RD ? GTR; thiotepa, CBDCA; SCT; DoD, 12 m [10]
24 m/M L temp-pariet. STR ? 12 m RD ? STR; PD, 17 m [11]
33 m/F L pariet-occipit. STR; VCR, VP-16, CTX, MTX, IFO, ith: VP-16, Ara-C; SCT; RT: tb
54 Gy ? 10 m PD ? STR; THD, FF, celecoxib, CTX, BEV, VP-16
DoD, 15 m [12]
16 m/M Pineal gland STR; VCR, VP-16, CTX, CBDCA ? 6 m PD ? ChT; RT: tb: 50.4 Gy FoD, 15 m [13]
36 m/F L fronto-pariet. GTR; VCR, VP-16, CTX, CBDCA, thiotepa ? 8 m RD ? GTR; RT: CSI
proton RT ? 4 m PD ? TMZ, IRI, BEV
DoD, 13 m [14]
24 m/F L occipit.
cerebellum
GTR; VCR, VP-16, CTX, CBDCA, ith: MTX, Ara-C; BU, VP-16, thiotepa;
SCT ? 30 m RD ? STR;CRT: CSI 32 Gy, tb boost: 30 Gy with TMZ;
THD, FF, celecoxib, CTX, BEV, TMZ
FoD, 52 m Present
case
A age, G gender, Loc localization, FU follow-up, M male, F female, L left, R right, M month, ITH intrathecal, Ara-C cytarabine, BEV
bevacizumab, BU busulfan, CBDCA carboplatin, CDDP cisplatin, CTX cyclophosphamide, FF fenofibrate, IFO ifosfamide, IRI irinotecan, MTX
methotrexate, THD thalidomide, TMZ temozolomide, VCR vincristine, VP-16 etoposide, GTR gross total resection, STR subtotal resection, ChT
chemotherapy, CRT chemo-radiotherapy, CSI craniospinal axis irradiation, RT radiotherapy, SCT stem cell transplantation, TB tumor bed, DoD
died of disease, FoD free of disease, PD progressive disease, RD recurrent disease
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long survivors (at least 30 months after diagnosis) with
ETANTR (Table 2). The mean age at diagnosis was
31.2 months (range 7–48 months), with a male: female
ratio of 3:3. At the time of the report each of the 6 children
was free of disease. They were all operated: 2/6 STR and
4/6 GTR. 1 child who did not receive adjuvant therapy [1]
was reoperated 11 months after the first surgery because of
tumor recurrence and then received combined ChT fol-
lowed by SCT. The other 5 children received high-dose
ChT in various combinations. RT was applied in 4 cases:
hyperfractionated CSI with 36 Gy and a 30 Gy tb boost
followed by 8 cycles of carboplatin, vincristine and
lomustine [15]; CSI with 36 Gy and a 19.8 Gy tb boost
supplemented with concurrent carboplatin and vincristine
followed by cisplatin, vincristine, and cyclophosphamide
[10] (to date he is the longest survivor); and in our case,
CSI with 32 Gy and a 30 Gy tb CRT supplemented with
concomitant temozolomide, and thereafter 150 mg/m2
mono temozolomide monthly up to September 2014. The
similarities of these cases are that all 6 children were
operated after diagnosis, at least STR was performed and
combined high-dose ChT was administered for a certain
amount of time.
RT is often problematic in the cases of such young
children. To avoid major late side-effects (e.g. neurocog-
nitive deficit, intellectual loss, hearing and visual impair-
ment, endocrine dysfunction, asymmetry of the bony and
muscular structures, or second malignancies), it is recom-
mended to use the most conformal technique available and
delay it as long as possible [33]. In contrast CSI RT is an
important part of the treatment protocol of aggressive
pediatric medulloblastoma and PNETs [34] and this tech-
nique has revealed its benefits in other malignancies with a
high tendency to spread along the entire neuroaxis [35].
ETANTR most frequently occurs supratentorially (70.3 %)
but has been described at all sites in the CNS [9] and
metastatic cases have been reported, too [24]. This malig-
nant feature and the very frequently reported poor outcome
underline the need for aggressive multimodal therapy,
which should include CSI RT, too. In our case, we deliv-
ered CRT for the time of tb irradiation with 30 Gy sup-
plemented with 75 mg/m2 temozolomide after 32 Gy CSI
RT and continued only on temozolomide. The CRT and the
subsequent ChT were very well tolerated, and the girl is
free of disease 52 months after the initial diagnosis. The
currently longest survivor [10] received CSI and tb boost
CRT with carboplatin and vincristine, continued on ChT
with cisplatin, vincristine and cyclophosphamide, and is
free of disease 84 months after the diagnosis. These 2 cases
appear to suggest that the implementation of CRT may
result in long-term disease-free survival. Temozolomide
may be better tolerated than carboplatin, vincristine, cis-
platin, and cyclophosphamide even by young children and
might cause fewer side-effects, but a long-term follow-up
is strongly recommended.
In our case report, as well as in many other case reports
cited here, neither LIN28 immunostaining nor C19MC
amplification analysis were performed. For the appropriate
diagnosis these analyses seem to be essential to distinguish
between subtypes of embrional tumors and prognosticate
favourable and unfavourable clinical course [4, 19, 26–28,
37]. The correct diagnosis is absolutely necessary to choose
the best possible treatment. It might be benefitial to per-
form LIN28 immunostaining and/or C19MC amplification
analysis in further suspected cases of ETANTR to provide
the exact diagnosis.
Table 2 Reported cases of ETANTR with long-term survival (at least 30 months)
A/G Loc. Treatment Outcome/FU Ref.
24 m/F L front. STR ? 11 m RD ? STR; IFO, CBDCA, VP-16; SCT FoD, 30 m [1]
36 m/F L front. STR; ChT; RT FoD, 42 m [2]
7 m/M L temp-pariet. GTR; VCR, CDDP, VP-16, CTX, MTX FoD, 48 m [9]
48 m/M R pariet. GTR; CRT: CSI 36 Gy, tb boost: 19.8 Gy with CBDCA, VCR;
CDDP, VCR, CTX
FoD, 84 m [10]
48 m/M Pons,
mesencephalon
GTR; MTX, VCR, VP-16, CTX, VCR, CDDP; RT: CSI 36 Gy,
twice a day 1 Gy/fr, tb boost 30 Gy, twice a day 1 Gy/fr; 8
cycles: CBDCA, VCR, CCNU
FoD, 34 m [15]
24 m/F L cerebellum
and occipit.
GTR; VCR, VP-16, CTX, CBDCA, ith: MTX, Ara-C, SCT, BU,
VP-16, thiotepa ? 30 m RD ? STR;C RT: CSI 32 Gy, tb
boost: 30 Gy with TMZ; THD, FF, celecoxib, CTX, BEV; TMZ
FoD, 52 m Present
case
A age, G gender, Loc localization, FU follow-up, M male, F female, L left, R right, M month, ITH intrathecal, Ara-C cytarabine, BEV
bevacizumab, BU busulfan, CBDCA carboplatin, CCNU lomustine, CDDP cisplatin, CTX cyclophosphamide, FF fenofibrate, IFO ifosfamide,
MTX methotrexate, THD thalidomide, TMZ temozolomide, VCR vincristine, VP-16 etoposide, GTR gross total resection, STR subtotal resection,
ChT chemotherapy, CRT chemoradiotherapy, CSI craniospinal axis irradiation, RT radiotherapy, SCT stem cell transplantation, TB tumor bed,
FoD free of disease
J Neurooncol (2016) 126:99–105 103
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Conclusions
ETANTR has been identified as a histologically distinctive
CNS embryonal tumor. Since the first description by
Eberhart et al. in 2000 [1], we have found 69 reported
cases, including our own case. Usually young children
under the age of 4 years are affected. ETANTR is associ-
ated with a dismal prognosis due to its highly malignant
course, but some case reports show that long-term disease-
free survival can be achieved through radical tumor
resection, ChT, SCT and RT. RT of the entire CSI is
strongly recommended because ETANTR can spread via
the cerebrospinal fluid. The delivery of CRT can result in a
survival benefit, and temozolomide may be less toxic and
better tolerated by young children. A long-term follow-up
appears necessary and further detailed molecular profiling
[36, 37] promote an understanding of the genetic back-
ground and molecular mechanism of this rare tumor type
and could lead to targeted and more effective therapies.
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